Compounds and compositions for the treatment of ocular disorders

1. A compound of Formula XV:

or a pharmaceutically acceptable salt thereof;

wherein:

R 32 is R 35 ;

R 35 is selected from

x and y are integers independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30.

2. The compound of claim 1 , wherein x and y are independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.

3. The compound of claim 2 , wherein y is selected from 1, 2, 3, 4, 5, or 6.

4. The compound of claim 2 , wherein x is 1 and y is selected from 1, 2, 3, 4, 5, or 6.

5. The compound of claim 2 , wherein x is 2 and y is selected from 1, 2, 3, 4, 5, or 6.

6. The compound of claim 2 , wherein x is 1 and y is 1.

7. The compound of claim 2 , wherein x is 1 and y is 2.

8. The compound of claim 2 , wherein x is 1 and y is 3.

9. The compound of claim 2 , wherein x is 1 and y is 4.

10. The compound of claim 1 , wherein R 35 is

11. The compound of claim 10 , wherein x and y are independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.

12. The compound of claim 11 , wherein y is selected from 1, 2, 3, 4, 5, or 6.

13. The compound of claim 11 , wherein x is 1 and y is selected from 1, 2, 3, 4, 5, or 6.

14. The compound of claim 11 , wherein x is 2 and y is selected from 1, 2, 3, 4, 5, or 6.

15. The compound of claim 13 , wherein x is 1 and y is 1.

16. The compound of claim 13 , wherein x is 1 and y is 2.

17. The compound of claim 13 , wherein x is 1 and y is 3.

18. The compound of claim 13 , wherein x is 1 and y is 4.

19. The compound of claim 1 , wherein R 35 is

20. The compound of claim 19 , wherein x and y are independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.

21. The compound of claim 20 , wherein y is selected from 1, 2, 3, 4, 5, or 6.

22. The compound of claim 19 , wherein x is 1 and y is selected from 1, 2, 3, 4, 5, or 6.

23. The compound of claim 19 , wherein x is 2 and y is selected from 1, 2, 3, 4, 5, or 6.

24. The compound of claim 19 , wherein x is 1 and y is 1.

25. The compound of claim 19 , wherein x is 1 and y is 2.

26. The compound of claim 19 , wherein x is 1 and y is 3.

27. The compound of claim 19 , wherein x is 1 and y is 4.

28. The compound of claim 1 of the formula

or a pharmaceutically acceptable salt thereof.

29. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

30. A method for the treatment of an ocular disorder treatable with both a beta-blocker and a tyrosine kinase inhibitor comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof of claim 1 to a host in need thereof wherein the disorder is selected from glaucoma, age-related macular degeneration (AMD), a disorder related to an increase in intraocular pressure (IOP), a disorder related to neuroprotection, diabetic retinopathy, or optic nerve damage caused by high intraocular pressure (IOP).

31. The method of claim 30 , wherein the disorder is glaucoma.

32. The method of claim 30 , wherein the disorder is related to an increase in intraocular pressure (IOP).

33. The method of claim 30 , wherein the disorder is optic nerve damage caused by high intraocular pressure (IOP).

34. The method of claim 30 , wherein the disorder is related to neuroprotection.

35. The method of claim 30 , wherein the host is a human.

36. The method of claim 30 , wherein the compound is administered via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, choroidal, subchoroidal, conjunctival, subconjunctival, episcleral, posterior juxtascleral, circumcorneal, or tear duct injection.

37. The method of claim 36 , wherein the compound is administered via intravitreal injection.